MSF's publications are an expression of our belief in the principle of témoignage, or bearing witness, and the belief that we are accountable to those we work for and with. Sharing news about our activities and reflecting on them, offering critiques when necessary, are therefore crucial aspects of our work.

View and download these publications below.

To view the U.S. Annual Reports or International Activity Reports, please visit the Annual Reports page.

Country/Region

October 25, 2016

South Africa has one of the highest burdens of tuberculosis (TB) and drug-resistant tuberculosis (DR-TB) in the world, with more than 20,000 people diagnosed with DR-TB in 2015. Yet the current DR-TB treatment regimen—which consists of a combination of multiple pills and daily injections—is only successful in about half of all people who receive it. New drugs such as delamanid offer the opportunity to provide more successful, tolerable treatment regimens to patients with few other options available.

September 14, 2016

New report exposes pharmaceutical industry failings and highlights new ways of researching and developing medicines that address public health needs.

July 19, 2016

Durban, South Africa—Global HIV/AIDS leaders at the International AIDS Conference in Durban must develop and implement an action plan to address the critical lack of access to HIV treatment in countries in West and Central Africa where coverage remains below 30 percent, said the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) Tuesday.

April 20, 2016

Globally, the years 2000 to 2015 saw the scaling-up of access to antiretroviral therapy (ART), with a 35 percent decrease in AIDS-related deaths since 2005. A record number of almost 16 million people living with HIV (PLHIV) have been initiated on ART as of mid-2015, three in four of whom live in sub-Saharan Africa, where the needs are most acute. Civil society and public health services alike have rallied to bring new evidence-based treatments and best practices to PLHIV.

March 21, 2016

New York/Geneva, March 21, 2016—Two years after two new drugs to treat tuberculosis (TB)—the first in over 50 years—were conditionally approved for use, only two percent of the 150,000 people who need them most have been able to access them, according to Doctors Without Borders’ new edition of DR-TB Drugs Under the Microscope.

December 01, 2015

Lifesaving antiretroviral medicines (ARVs) are routinely not making their way to patients in sub-Saharan Africa, most often despite sufficient stocks already being present in countries.

December 01, 2015

It’s World AIDS Day, and it’s time to prove HIV is in no way an automatic death sentence. The people of Khayelitsha township in Cape Town, South Africa, in creative collaboration with Doctors Without Borders/Médecins Sans Frontières (MSF), activists, artists and musicians, came together to urge young people to stand strong against the virus: "This mural is for us . . . It is made by the people of Khayelitsha."

November 30, 2015

Click Here to Download the Full Report

Despite considerable investments in supply chain reforms, wide-spread medicines stock outs negatively constrain patients’ ability to have access to their medication. Limited availability of antiretroviral drugs (ARVs) caused by dysfunctional supply chains impedes patient initiation and adherence and poses a major barrier to win the global fight against HIV.

November 30, 2015

JOHANNESBURG/HARARE—The international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) today warned that lifesaving antiretroviral medicines (ARVs) are routinely not making their way to patients in sub-Saharan Africa, most often despite sufficient stocks already being present in countries, and called for urgent improvements in ARV supply chains in the region.

October 28, 2015

JOHANNESBURG—After six months of persistent supply problems with the key HIV medicine lopinavir/ritonavir (LPV/r), the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) urged the South African government to put the public’s health first and override pharmaceutical company AbbVie’s patent with a "compulsory licence," in order to allow generic versions of LPV/r to be used in the country.

Pages

October 25, 2016

South Africa has one of the highest burdens of tuberculosis (TB) and drug-resistant tuberculosis (DR-TB) in the world, with more than 20,000 people diagnosed with DR-TB in 2015. Yet the current DR-TB treatment regimen—which consists of a combination of multiple pills and daily injections—is only successful in about half of all people who receive it. New drugs such as delamanid offer the opportunity to provide more successful, tolerable treatment regimens to patients with few other options available.

September 14, 2016

New report exposes pharmaceutical industry failings and highlights new ways of researching and developing medicines that address public health needs.

July 19, 2016

Durban, South Africa—Global HIV/AIDS leaders at the International AIDS Conference in Durban must develop and implement an action plan to address the critical lack of access to HIV treatment in countries in West and Central Africa where coverage remains below 30 percent, said the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) Tuesday.

April 20, 2016

Globally, the years 2000 to 2015 saw the scaling-up of access to antiretroviral therapy (ART), with a 35 percent decrease in AIDS-related deaths since 2005. A record number of almost 16 million people living with HIV (PLHIV) have been initiated on ART as of mid-2015, three in four of whom live in sub-Saharan Africa, where the needs are most acute. Civil society and public health services alike have rallied to bring new evidence-based treatments and best practices to PLHIV.

March 21, 2016

New York/Geneva, March 21, 2016—Two years after two new drugs to treat tuberculosis (TB)—the first in over 50 years—were conditionally approved for use, only two percent of the 150,000 people who need them most have been able to access them, according to Doctors Without Borders’ new edition of DR-TB Drugs Under the Microscope.

December 01, 2015

Lifesaving antiretroviral medicines (ARVs) are routinely not making their way to patients in sub-Saharan Africa, most often despite sufficient stocks already being present in countries.

December 01, 2015

It’s World AIDS Day, and it’s time to prove HIV is in no way an automatic death sentence. The people of Khayelitsha township in Cape Town, South Africa, in creative collaboration with Doctors Without Borders/Médecins Sans Frontières (MSF), activists, artists and musicians, came together to urge young people to stand strong against the virus: "This mural is for us . . . It is made by the people of Khayelitsha."

November 30, 2015

Click Here to Download the Full Report

Despite considerable investments in supply chain reforms, wide-spread medicines stock outs negatively constrain patients’ ability to have access to their medication. Limited availability of antiretroviral drugs (ARVs) caused by dysfunctional supply chains impedes patient initiation and adherence and poses a major barrier to win the global fight against HIV.

November 30, 2015

JOHANNESBURG/HARARE—The international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) today warned that lifesaving antiretroviral medicines (ARVs) are routinely not making their way to patients in sub-Saharan Africa, most often despite sufficient stocks already being present in countries, and called for urgent improvements in ARV supply chains in the region.

October 28, 2015

JOHANNESBURG—After six months of persistent supply problems with the key HIV medicine lopinavir/ritonavir (LPV/r), the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) urged the South African government to put the public’s health first and override pharmaceutical company AbbVie’s patent with a "compulsory licence," in order to allow generic versions of LPV/r to be used in the country.

Pages